Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 March 2026.
All research outputs
#1,828,192
of 34,089,221 outputs
Outputs from Journal of Clinical Oncology
#5,091
of 32,061 outputs
Outputs of similar age
#15,223
of 266,665 outputs
Outputs of similar age from Journal of Clinical Oncology
#58
of 251 outputs
Altmetric has tracked 34,089,221 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32,061 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.2. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,665 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 251 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.
